Un petit nouveau dans les traitements lié au GcMaf : le
RerumQuelques infos pour ceux que ça intéréssent...
Pti gars
------------------------------
For many years it was erroneously believed that GcMAF (GcProtein) was a conductor in the innate immune system and an extremely powerful endogenous macrophage stimulator.
Professor Ruggiero and a number of other research groups however have discovered that there are different phenotypes in humans leading to different coding regions for amino acids for the human Vitamin-D binding protein (DBP). This is due to allelic differences: one group of GC polymorphisms, the GC1 group, has a threonine residue whilst the GC2 group has a lysine residue.
The possible genetic alternatives in GC1 and GC2 groups on the same genetic locus lead to completely new conclusions being drawn about GcMAF being the only protein-derived MAF (DBP) in healthy human bodies. If there are humans without a threonine coding for GcMAF, in other words subjects homozygous for GC2 and therefore with a lysine coding instead, they would not have a single molecule of GcMAF in their bodies; therefore their immune system would be weak and they would have a much higher risk of developing cancer. But this is not the case.
On the other hand, studies around the world by many researchers have demonstrated, amongst other things, that the activation of macrophages produces pro-immunogenic, anti-inflammatory, neuro-protective and even anti-cancer/anti-angiogenetic effects. So how can we explain the efficiency of such an immune modulation via GcMAF if the entire theory surrounding GcMAF is incorrect?
The answer seems rather simple. Professor Ruggiero believes that the answer lies in the molecular structure of GcMAF, which contains vitamin D and fatty acids, in particular oleic acid and chondroitin sulfate. The effects observed in GcMAF are solely due to its function as a carrier protein. The GcProtein itself has no effect per se; it only serves to carry the molecules endowed with all the effects erroneously attributed to GcMAF.
And what about oleic acid and vitamin D? Could other effects previously and erroneously attributed to GcMAF be due to vitamin D and oleic acid instead? Indeed, numerous studies now show the benefits of these substances in different diseases.
This knowledge enabled Professor Ruggiero to reconstitute all the effects and even boost the power of the aforementioned structure by designing the proper Macrophage Activating Factor: as Rerum®. This is a new generation MAF without the GcMAF protein itself. In the newly developed Rerum®, the protein backbone is replaced by chondroitin sulfate.
While GcMAF from human blood protein only has one chemical bond for certain moieties, chondroitin has more than 50 moieties for N-Acetylgalctosamine (GalNac). Rerum® demonstrates the effects attri- buted to GcMAF, and even goes so far as to also show those properties that have long been linked to chondroitin sulfate.
Source:
http://www.rareandbrave.com/